Medical Industry Feature: Managing mCRC Based on Prognostic Factors

Be part of the knowledge.

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Managing mCRC Based on Prognostic Factors

Program Information

Managing mCRC Based on Prognostic Factors

BRAF mutation has important genetic, prognostic, and therapeutic implications for patients with metastatic colorectal cancer, as these studies show.

  • Overview

    This program is intended for healthcare professionals only and is developed by Merck KGaA, Darmstadt, Germany.

    Tune in as Professor Volker Heinemann shares his perspective on whether the Consensus Molecular Subtype is ready for clinical practice, the implications of the BRAF mutations, and the current and future advances in the management of patients with metastatic colorectal cancer (mCRC).


LIVE ON REACHMD RADIOBack to live radio


Programs 1/22/21